Aspirus Health has been administering COVID-19 antibody treatments throughout the pandemic and continues to see them produce positive outcomes. Aspirus recently partnered with Canal View – Houghton County to administer the COVID-19 antibody treatments to residents who were COVID-positive.

“We are extremely grateful for Aspirus Health leading the way to help reduce COVID-19, hospitalizations, and offering Regen-Cov as an option for our most vulnerable population,” said Kim Salmi, Administrator, Canal-View Houghton County. “Unfortunately, the delta variant has made its way into our facility despite all efforts. We can’t thank Aspirus enough for providing this treatment.”

The treatment, called Regen-Cov, can be administered through an intravenous (IV) infusion or, in some cases, through subcutaneous injection.

“We are grateful Regen-Cov is available for patients at high risk for progressing to severe illness or hospitalization due to COVID-19,” said Jessica Bessner, director – Aspirus regional pharmacies. “The health and safety of our communities always comes first, and we are grateful to be here providing care to those when they need it most.”

Aspirus began offering COVID-19 antibody treatments in November of last year and has successfully administered 477 infusions across its system.

People who have tested positive for COVID-19 must meet specific criteria to be eligible for antibody therapy. Eligible people include those ages 12 and older weighing more than 90 pounds and has one or more of the following high-risk factors, including: obesity, pregnant, or those who have chronic disease such as diabetes, kidney, lung, or heart disease, hypertension or any immunosuppressive disease.

Aspirus actively identifies patients appropriate for treatment and encourages anyone who tests positive for COVID-19 to talk to their primary care provider if they feel they meet the above criteria.

Aspirus urges everyone who is eligible to get vaccinated as data indicates that those who remain unvaccinated are at higher risk for severe illness due to COVID-19.